医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Signostics Appoints Former SonoSite Executives in US and Japan

2015年07月15日 PM09:00
このエントリーをはてなブックマークに追加


 

ADELAIDE, Australia

Following the recent appointment of former SonoSite Inc. CEO and medical ultrasound pioneer Kevin Goodwin as CEO, Australian medical device company Signostics has announced the appointment of Rick Salzar and Takatsuna Kitagawa, both former SonoSite Executives, as the company’s new Vice President of Global Distribution and Managing Director Japan, respectively.

Mr Salzar, who is based in California, has 33 years’ experience in the medical device industry, with 25 years in International Management positions for Alaris Medical Systems specialising in the intravenous drug delivery market.

In 2011, Mr Salzar moved from Alaris Medical Systems to a position as the SonoSite Vice President and General Manager of Europe, Russia and Africa. Mr Salzar’s tenure at SonoSite was credited with many notable achievements including leading the company in the reorganisation of the entire go-to-market team and strategy. Under Mr Salzar’s leadership, SonoSite also successfully launched their newest product, the X-Porte point-of-care device.

Mr Kitagawa, who is based in Japan, has 24 years’ experience in the ultrasound industry, with 10 years in management positions for SonoSite Japan.

After experience in business development roles for SonoSite Japan, Mr Kitagawa moved to a position as the company’s General Manager. Mr Kitagawa’s tenure at SonoSite was credited with many prominent achievements including receiving the Chairman’s Award and Country of the Year award. Under Mr Kitagawa’s leadership, SonoSite Japan also achieved the largest revenue and profit of all SonoSite subsidiaries outside of the US.

Chief Executive Officer of Signostics Kevin Goodwin is delighted to confirm the appointment of Mr Salzar and Mr Kitagawa.

“I’m pleased to announce that we have attracted Mr Salzar and Mr Kitagawa to Signostics. They both bring us a track record of consistent reliable performance,” Mr Goodwin said.

Mr Salzar and Mr Kitagawa both said they were excited about the opportunity to join Signostics.

“I have known of Signostics for quite some time as I was an investor in needle guidance technology for line placement in anaesthesia and I was familiar with the small size and leading edge technology.

“When I learned Kevin Goodwin had joined, I was very interested in how Signostics could grow into a global ultrasound player. I was convinced that a small, agile company could develop technology faster and differentiate itself quickly from other companies in the market,” Mr Salzar said.

“Signostics has a great chance to be a global leader in the forthcoming new ultrasound market, especially in the area of point-of-care as a new ultrasound tool for everyone,” Mr Kitagawa said.

Mr Salzar and Mr Kitagawa took up their appointments from 22 June, 2015 and 1 July, 2015, respectively.

About Signostics:
Signostics Inc. is a wholly owned subsidiary of Signostics Limited. Signostics Limited is an Australian medical device manufacturer and a market leader in handheld ultrasound devices and bladder scanners. Products include the SignosRT ultrasound system and the SignosRT Bladder, both ultra-portable, affordable devices designed to assist with the diagnosis of common medical presentations at the bedside. The company has regulatory approvals in place for Australia, the U.S., Canada, Japan, Singapore and Europe and currently exports to countries around the world.

More information:
www.signostics.com.au
Twitter: @signostics

View source version on businesswire.com: http://www.businesswire.com/news/home/20150715005605/en/

CONTACT

For media enquiries contact:
Signostics
Tegan Syrus,
+61-8-7424-0600
Marketing Coordinator
media@signostics.com.au

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作